Other-Net, Expense (Income)

3 Months Ended

Mar. 31, 2014

Nonoperating Income (Expense) [Abstract]

Other - Net, Expense (Income) [Text Block]

Note 13: Other–Net, (Income) Expense

Other–net, (income) expense consisted of the following:

	Three Months Ended
	March 31,
	2014			2013
Interest expense	$	37.8		$	40.3
Interest income	(34.4		)	(23.6		)
Income related to termination of the exenatide collaboration with Amylin (Note 4)	—			(495.4		)
Other	(59.4		)	(50.5		)
Other–net, (income) expense	$	(56.0	)	$	(529.2	)

Other–net, income of $529.2 million for the first three months of 2013 is primarily related to the income recognized from the transfer to Amylin of exenatide commercial rights in all markets outside the United States. See Note 4 for additional information.